CN117534658A - 一种靶向降解CK1α蛋白并激活P53蛋白的化合物及其应用 - Google Patents
一种靶向降解CK1α蛋白并激活P53蛋白的化合物及其应用 Download PDFInfo
- Publication number
- CN117534658A CN117534658A CN202311514297.9A CN202311514297A CN117534658A CN 117534658 A CN117534658 A CN 117534658A CN 202311514297 A CN202311514297 A CN 202311514297A CN 117534658 A CN117534658 A CN 117534658A
- Authority
- CN
- China
- Prior art keywords
- amino
- compound
- protein
- pharmaceutically acceptable
- fluoropyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 46
- 230000006303 immediate early viral mRNA transcription Effects 0.000 title claims abstract description 16
- 230000015556 catabolic process Effects 0.000 title abstract description 9
- 238000006731 degradation reaction Methods 0.000 title abstract description 9
- 230000004913 activation Effects 0.000 title abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000004677 hydrates Chemical class 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims abstract description 3
- -1 4- ((3- ((4- (5- (cyclopropylmethyl) -1-methyl-1H-pyrazol-4-yl) -5-fluoropyrimidin-2-yl) amino) propyl) amino) -2- (2, 6-dioxopiperidin-3-yl) isoindoline-1, 3-dione Chemical compound 0.000 claims description 15
- 102100034356 Casein kinase I isoform alpha-like Human genes 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000003733 ovarian melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000004952 protein activity Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000034512 ubiquitination Effects 0.000 abstract description 3
- 238000010798 ubiquitination Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 229940076376 protein agonist Drugs 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 5
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 5
- 108010026668 snake venom protein C activator Proteins 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- DWOZNANUEDYIOF-UHFFFAOYSA-L 4-ditert-butylphosphanyl-n,n-dimethylaniline;dichloropalladium Chemical compound Cl[Pd]Cl.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 DWOZNANUEDYIOF-UHFFFAOYSA-L 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940121649 protein inhibitor Drugs 0.000 description 2
- 239000012268 protein inhibitor Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- CRAUTELYXAAAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione Chemical compound O=C1C=2C(F)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O CRAUTELYXAAAPW-UHFFFAOYSA-N 0.000 description 1
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125801 compound 7f Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004427 diamine group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 1
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及药物化学领域，公开一种靶向降解CK1α蛋白并激活P53蛋白的化合物及其应用，具体涉及一种可靶向泛素化降解CK1α蛋白并激活P53蛋白的化合物，及其药学上可接受的盐、水合物，和以该化合物为活性成分的药物组合，以及在制备CK1α蛋白降解剂及P53蛋白激动剂及其用于治疗和/或预防癌症中的用途。本发明所述的化合物、及其药学上可接受的盐，水合物结构如下：其变量如权利要求和说明书所述。
Description
技术领域
本发明涉及医药技术领域，特别是涉及一种可靶向降解CK1α蛋白并激活P53蛋白的化合物，及其药学上可接受的盐，水合物和以该化合物为活性成分的药物组合，以及在制备CK1α蛋白抑制和降解剂及P53蛋白激动剂及其用于治疗和/或预防肿瘤中的应用。
背景技术
CK1α的表达异常与肿瘤的发生、发展有着密切联系,研究表明通过抑制或敲除CK1α蛋白可激活肿瘤抑制蛋白p53,从而达到治疗肿瘤得作用(Cell.2018 Sep 20；175(1):171-185.e25.)。
PROTAC是一种通过双功能小分子将目标蛋白和细胞内的E3拉近，从而导致靶向蛋白泛素化降解的技术。相对于传统靶向药物具有可突破不可成药靶点和抗耐药等优点。本发明设计合成一种新型PROTAC化合物，选用沙利度胺类似物作为PROTAC中与E3连接酶进行结合的部位，选用不同长度和不同类型连接链将其与具有CK1α蛋白抑制剂活性的结构相连接构建PROTAC。体外抗肿瘤活性测试及体外CK1α蛋白和P53蛋白表达实验表明，系列化合物可将CK1α蛋白降解并激活P53蛋白，并具有良好的抗肿瘤活性。
发明内容
本发明目的在于提供一种具有泛素化降解CK1α蛋白和激活P53蛋白的化合物及其制备方法，以及该类化合物作为CK1α蛋白降解剂及P53蛋白激活剂在预防和/或治疗肿瘤中的应用。
本发明设及通式Ⅰ所示的化合物、及其药学上可接受的盐或水合物：
其中连接链linker各自独立的选自烷基链n为1-20；
PEG链n为1、2、3、4、5或6。
此外，本发明包括药物组合物，该组合物含有通式Ⅰ化合物和药物上可接受的赋形剂。所述药物上可接受的赋形剂是指任何可用于药物领域的稀释剂、辅助剂和/或载体。本发明的化合物可以与其他活性成分组合使用，只要它们不产生其它不利作用，例如过敏反应。
本发明的药物组合可配置成若干剂型，其中含有药物领域中常用的一些赋形剂，例如，口服制剂(如片剂，胶囊剂，溶液或混悬液)；可注射的制剂(如可注射的溶液或混悬剂，或者是可注射的干燥粉末，在注射前加入注射用水可立即使用)；局部制剂(例如软膏或溶液)。
用于本发明药物组合物的载体是药物领域中可得到的常见类型，包括：口服制剂用的粘合剂、润滑剂、崩解剂、助溶剂、稀释剂、稳定剂、悬浮剂、色素、矫味剂等；可注射制剂用的防腐剂、加溶剂、稳定剂等；局部制剂用的基质、稀释剂、润滑剂、防腐剂等。药物制剂可以经口服或胃肠外方式(例如静脉内、皮下、腹膜内或局部)给药，如果某些药物在胃部条件下是不稳定的，可将其配制成肠衣片剂。通过体外试验筛选，我们发现本化合物具有降解CK1α蛋白和激活P53蛋白活力。因此，本发明化合物可用于与CK1α和P53蛋白异常表达相关的疾病中的应用，如各种癌症。
通过体外活性筛选，我们发现本发明化合物具有抗肿瘤活性，因此本发明化合物可以用于制备治疗和/或预防各种癌症的药物，如乳腺癌，结肠癌，前列腺癌，胰腺癌，非小细胞肺癌，甲状腺乳头状癌，卵巢癌、黑色素瘤、或各种白血病。
本发明化合物可作为唯一的抗癌药物使用，或者与一种或多种其它抗肿瘤药物联合使用。联合治疗通过将各个治疗组分同时，顺序或隔开给药来实现。
下文中提供的实施例和制备例进一步阐明和举例说明本化合物及其制备方法。应当理解，下述实施例和制备例的范围并不以任何方式限制本发明的范围。
下面的合成路线描述了本发明的通式I化合物的制备，所有的原料都是通过这些路线中描述的方法、通过有机化学领域普通技术人员熟知的方法制备的或者可商购。本发明的全部最终化合物都是通过这些路线中描述的方法或通过与其类似的方法制备的，这些方法是有机化学领域普通技术人员熟知的。这些路线中应用的全部可变因数如下文的定义或如权利要求中的定义。
按照本发明的通式I化合物，合成路线中各取代基如发明内容部分所定义。
本发明制备方法操作简单，条件温和，所得化合物均具有CK1α蛋白降解和P53蛋白激活活性，抗肿瘤作用显著。
中间体2的制备
化合物1(12.0g，146.3mmol)，四氢呋喃240mL，-78℃加入正丁基锂70mL。搅拌1h后加入环丙甲醛(12.3g，175.6mmol)的四氢呋喃溶液120mL溶液。搅拌过夜，加入饱和氯化铵水溶液500mL，水相用乙酸乙酯萃取三次，无水硫酸钠干燥，蒸干柱层析(石油醚:乙酸乙酯＝10：1)得无色油状物化合物2(17.5g，产率79％)。
1H NMR(400MHz，CDCl3)δ：7.21(d，J＝2.0Hz，1H)，6.19(d，J＝2.0Hz,1H)，4.46(s，1H)，4.02(d，J＝8.0Hz，1H)，3.76(s，3H)，1.29-1.23(m，1H)，0.64-0.50(m，2H)，0.44-0.38(m，1H)，0.29-0.23(m，1H)。
中间体3的制备
化合物2(15.2g，100mmol)、三氟乙酸(68.4g，600mmol)和Et3SiH(70.0g，600mmol)溶于二氯甲烷1200mL，室温搅拌36h。NaHCO3水溶液调pH＝8，二氯甲烷萃取3次。无水硫酸钠干燥，蒸干柱层析(石油醚:乙酸乙酯＝50：1)得无色油状物化合物3(7.0g，51％)。
1H NMR(400MHz，CDCl3)δ：7.39(s，1H)，6.19(s，1H)，3.79(s，3H)，2.52(d，J＝8.0Hz，2H)，1.06-0.96(m，1H)，0.60-0.55(m，2H)，0.20-0.18(m，2H)。
中间体4的制备
化合物3(7.0g，51.5mmol)加入二氯甲烷100mL，加入NBS(11.0g，61.8mmol)，室温反应2h。蒸干柱层析(石油醚:乙酸乙酯＝50：1)得化合物4(8.0g，73％)。
1H NMR(400MHz，CDCl3)δ：7.39(s，1H)，3.86(s，3H)，2.52(d，J＝8.0Hz，2H)，1.00-0.91(m，1H)，0.54-0.49(m，2H)，0.28-0.24(m，2H)。
中间体5的制备
化合物4(8.0g，37.2mmol)加入四氢呋喃150mL，-78℃加入正丁基锂(28.0mL,56.0mmol)。反应0.5h后，加入异丙醇频哪醇硼酸酯(15.0g，74.4mmol)的四氢呋喃溶液20mL。室温反应1.0h。加入饱和NH4Cl水溶液300mL，乙酸乙酯萃取3次，无水硫酸钠干燥，蒸干柱层析(石油醚:乙酸乙酯＝20：1)得化合物5(8.8g，90％)。
1H NMR(400MHz，CDCl3)δ：7.67(s，1H)，3.86(s，3H)，2.78(d，J＝8.0Hz，2H)，1.29(s，12H)，0.97-0.89(m，1H)，0.46-0.41(m，2H)，0.29-0.25(m，2H)。
中间体6的制备
化合物5(8.00g，30.5mmol)、2，4-二氯-5-氟嘧啶(6.1g，36.6mmol)、Na2CO3(7.1g，33.6mmol)和Pd(amphos)Cl20.3g加入乙二醇二甲醚150mL，氮气保护下85℃下反应2h。加水150mL，乙酸乙酯萃取3次，无水硫酸钠干燥，蒸干柱层析(石油醚:乙酸乙酯＝10：1)得化合物6(6.0g，75％)
1H NMR(400MHz，CDCl3)δ：8.36(d，J＝4.0Hz，1H),8.06(d，J＝4.0Hz，1H)，3.94(s，3H)，3.21(d，J＝8.0Hz，2H)，1.12-1.03(m，1H)，0.52-0.47(m，2H)，0.39-0.35(m，2H)。
中间体7的制备
化合物6(0.5g,1.9mmol),二胺基连接链2.3mmol，正丁醇10mL,160℃下反应8h,减压蒸干柱层析(二氯甲烷:甲醇＝1：1)得系列化合物7
化合物7a:1H NMR(400MHz，CD3OD)δ:8.11(d，J＝4.0Hz，1H),7.93(d，J＝4.0Hz，1H)，3.90(s，3H)，3.45(t,J＝8.0Hz,2H),3.32-3.30(m，2H),2.74(t,J＝8.0Hz,2H),1.81-1.74(m,2H),1.15-1.11(m,1H),0.50-0.45(m,2H),0.30-0.25(m,2H)。
化合物7b:1H NMR(400MHz，CDCl3)δ:8.05(d，J＝4.0Hz，1H),7.94(d，J＝4.0Hz，1H)，3.86(s，3H)，3.38(d,J＝4.0Hz,2H),3.11(d,J＝4.0Hz,2H),2.96(brs,2H),1.76-1.69(m,4H),1.06-1.03(m,1H),0.44-0.40(m,2H),0.21-0.17(m,2H)。
化合物7c:1H NMR(400MHz，CD3OD)δ:8.11(d，J＝4.0Hz，1H),7.94(d，J＝4.0Hz，1H)，3.91(s，3H)，3.41-3.35(m,2H),2.82(t,J＝4.0Hz,2H),1.67-1.58(m,4H),1.45-1.29(m,6H),1.16-1.12(m,1H),0.49-0.45(m,2H),0.30-0.26(m,2H)。
化合物7d:1H NMR(400MHz，CD3OD)δ:8.08(d，J＝4.0Hz，1H),7.92(d，J＝4.0Hz，1H)，3.91(s，3H)，3.36(t,J＝8.0Hz,2H),3.27(d,J＝8.0Hz,2H),2.94(t,J＝8.0Hz,2H),1.70-1.58(m,4H),1.39(brs,8H),1.16-1.08(m,1H),0.48-0.44(m,2H),0.30-0.26(m,2H)。
化合物7e:1H NMR(400MHz，CD3OD)δ:8.13(d，J＝4.0Hz，1H),7.94(d，J＝4.0Hz，1H)，3.91(s，3H)，3.66-3.59(m,4H),3.52(t,J＝4.0Hz,2H),3.27(d,J＝4.0Hz,2H),2.79(t,J＝4.0Hz,2H),1.16-1.10(m,1H),0.50-0.45(m,2H),0.30-0.26(m,2H)。
化合物7f:1H NMR(400MHz，CD3OD)δ:8.11(d，J＝4.0Hz，1H),7.92(d，J＝4.0Hz，1H)，3.90(s，3H)，3.69-3.62(m,8H),3.53(t,J＝4.0Hz,2H),3.24(d,J＝4.0Hz,2H),2.80(t,J＝4.0Hz,2H),1.15-1.08(m,1H),0.48-0.46(m,2H),0.29-0.27(m,2H)。
化合物7g:1H NMR(400MHz，CD3OD)δ:8.09(d，J＝4.0Hz，1H),7.91(d，J＝4.0Hz，1H)，3.88(s，3H)，3.65-3.55(m,12H),3.49(t,J＝4.0Hz,2H),3.23(d,J＝8.0Hz,2H),2.76(t,J＝4.0Hz,2H),1.13-1.06(m,1H),0.47-0.42(m,2H),0.27-0.23(m,2H)。
化合物8的制备
2-(2,6-二氧代-哌啶-3-基)-4-氟基-异吲哚-1,3-二酮(0.1g,0.36mmol)、化合物7(0.36mmol)和DIPEA 0.1mL加入DMF 5mL,100℃反应10h,加水50mL,乙酸乙酯萃取三次，有机相无水硫酸钠干燥，减压蒸干硅胶柱层析(甲醇：二氯甲烷＝1：20)，得化合物8。
具体实施方式
实施例1：化合物4-((3-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)丙基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮(8a)
1H NMR(400MHz，DMSO)δ:(11.10,s,1H),8.26(d，J＝4.0Hz，1H),7.83(d，J＝4.0Hz，1H),7.54(t，J＝8.0Hz，1H),7.16-6.99(m,3H),6.70(s,1H),5.07-5.03(m,1H),3.84(s,3H),3.17-3.15(m,2H),2.93-2.83(m,2H),2.60-2.50(m,3H),2.03-1.99(m,2H),1.86-1.82(m,2H),1.06-1.00(m,1H),0.35-0.33(m,2H),0.18(brs,2H)。LC-MS：[M+H]+561.4。
实施例2：4-((4-((5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)丁基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮(8b)
1H NMR(400MHz，DMSO)δ:11.08(s,1H),8.24(d，J＝4.0Hz，1H),7.83(d，J＝4.0Hz，1H),7.55(t，J＝8.0Hz，1H),7.09-7.00(m,3H),6.56-6.54(t，J＝4.0Hz，1H),5.06-5.02(m,1H),3.84(s,3H),3.10-3.17(m,2H),2.93-2.84(m,2H),2.61-2.53(m,1H),2.03-1.97(m,2H),1.64-1.63(m,4H),1.09-1.02(m,1H),0.39-0.34(m,2H),0.23-0.19(m,2H)。LC-MS：[M+H]+575.4
实施例3:4-((6-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)己基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮(8c)
1H NMR(400MHz，DMSO)δ:11.09(s,1H),8.23(d，J＝4.0Hz，1H),7.83(d，J＝4.0Hz，1H),7.55(t，J＝8.0Hz，1H),7.07-7.00(m,3H),6.51(t，J＝4.0Hz，1H),5.07-5.02(m,1H),3.85(s,3H),3.29-3.19(m,6H),2.93-2.83(m,1H),2.61-2.52(m,1H),2.04-1.96(m,2H),1.58-1.53(m,4H),1.39-1.36(m,4H)，1.08-1.04(m,1H),0.39-0.35(m,2H),0.23-0.19(m,2H)。LC-MS：[M+H]+603.4
实施例4:4-((8-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)辛基)氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮(8d)
1H NMR(400MHz，DMSO)δ:11.08(s,1H),8.23(d，J＝4.0Hz，1H),7.83(d，J＝4.0Hz，1H),7.56(t，J＝8.0Hz，1H),7.08-6.99(m,3H),6.50(t，J＝4.0Hz，1H),5.06-5.02(m,1H),3.85(s,3H),3.34-3.19(m,6H),2.93-2.83(m,1H),2.61-2.52(m,1H),2.04-1.99(m,2H),1.58-1.51(m,4H),1.31(brs,8H),1.07-1.03(m,1H),0.40-0.35(m,2H),0.23-0.20(m,2H)。LC-MS：[M+H]+631.7。
实施例5:4-((2-(2-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)乙氧基)乙基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮(8e)
1H NMR(400MHz，DMSO)δ:11.10(s,1H),8.23(d，J＝4.0Hz，1H),7.83(d，J＝4.0Hz，1H),7.54(t，J＝8.0Hz，1H),7.12-6.94(m,3H),6.61(t，J＝4.0Hz，1H),5.07-5.03(m,1H),3.84(s,3H),3.65-3.58(m,4H),3.49-3.44(m,4H),3.15(d,J＝4.0Hz,2H),2.93-2.84(m,1H),2.63-2.48(m,2H),2.04-1.99(m,2H),1.07-1.00(m,1H),0.37-0.34(m,2H),0.21-0.20(m,2H)。LC-MS：[M+H]+591.3。
实施例6:4-((2-(2-(((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)乙氧基)乙基)氨基)-2-(2,6-二氧嘧啶-3-基)异吲哚啉-1,3-二酮(8f)
1H NMR(400MHz，DMSO)δ:11.09(s,1H),8.23(d，J＝4.0Hz，1H),7.83(d，J＝4.0Hz，1H),7.55(t，J＝8.0Hz，1H),7.12-6.89(m,3H),6.59(t，J＝4.0Hz，1H),5.07-5.02(m,1H),3.84(s,3H),3.63-3.54(m,8H),3.43-3.36(m,4H),3.17(d,J＝8.0Hz,2H),2.91-2.82(m,1H),2.60-2.51(m,2H),2.04-1.97(m,2H),1.07-1.01(m,1H),0.40-0.35(m,2H),0.24-0.20(m,2H)。LC-MS：[M+H]+635.3。
实施例7:4-((2-(2-(-2-(2-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)乙氧基)乙氧氧基)乙基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二(8g)
1H NMR(400MHz，DMSO)δ:11.06(s,1H),8.22(d，J＝4.0Hz，1H),7.81(d，J＝4.0Hz，1H),7.53(t，J＝8.0Hz，1H),7.10-6.88(m,3H),6.56(t，J＝4.0Hz，1H),5.04-5.00(m,1H),3.83(s,3H),3.60-3.37(m,16H),3.15(d,J＝8.0Hz,2H),2.90-2.80(m,1H),2.58-2.51(m,2H),2.02-1.95(m,2H),1.06-1.00(m,1H),0.37-0.34(m,2H),0.21-0.19(m,2H)。LC-MS：[M+H]+679.3。
实施例8：MTT法测定肿瘤细胞增殖抑制活性
将处于细胞对数生长期的要进行实验的肿瘤细胞(MM1S细胞或A549细胞)按一定的细胞量接种于培养板内，培育24h，加入不同浓度抑制剂，细胞在37℃、5％CO2条件下继续培养72h，每孔加入20μL MTT溶液继续培养4h，用DMSO溶解结晶，用酶联免疫检测仪在570nm波长处测定其OD值计算IC50。
| 化合物编号 | MM1S IC50(nM) | A549 IC50(nM) |
| 1 | >1000 | >1000 |
| 2 | >1000 | >1000 |
| 3 | 658 | 532 |
| 4 | 350 | 462 |
| 5 | 532 | 480 |
| 6 | 164 | 182 |
| 7 | 84 | 96 |
实施例9：Western-blot测定CK1α和P53蛋白降解
将药物1uM干预12h的MM 1S细胞收集，用预冷的PBS洗涤2次，PMSF与RIPA裂解液以1：100的比例混合，冰上裂解细胞20min，4℃，12000r/min×20min离心，取上清，即细胞总蛋白，用BCA法定量检测蛋白量，用5×蛋白上样缓冲液稀释蛋白后100℃变性5min。蛋白在SDS-PAGE电泳分离，转膜，封闭2h，一抗4℃孵育过夜。TBST洗膜，二抗1:1000孵育2h，化学发光后X胶片显影，用Image J软件分析每个条带的灰度值，以0nM给药浓度下细胞蛋白表达作为100％，计算CK1α和P53蛋白表达量。
/>
Claims (6)
1.如通式Ⅰ所示的化合物、及其药学上可接受的盐或水合物：
其中连接链linker各自独立的选自烷基链n为1-20；
PEG链n为1、2、3、4、5或6。
2.根据权利要求1所述的化合物、及其药学上可接受的盐或水合物：选自，
4-((3-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)丙基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮；
4-((4-((5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)丁基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮；
4-((6-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)己基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮；
4-((8-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)辛基)氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮；
4-((2-(2-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)乙氧基)乙基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮；
4-((2-(2-(((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)乙氧基)乙基)氨基)-2-(2,6-二氧嘧啶-3-基)异吲哚啉-1,3-二酮；
4-((2-(2-(-2-(2-((4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)-5-氟嘧啶-2-基)氨基)乙氧基)乙氧氧基)乙基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮。
3.一种药物组合，其特征在于：包含权利要求1，2中任意一项的化合物、及其药学上可接受的盐或水合物以及药学上可接受的赋形剂。
4.权利要求1，2中任意一项的化合物、及其药学上可接受的盐或水合物和权利要求3所述药物组合在制备与CK1α蛋白和P53蛋白活性异常表达相关的疾病药物中的应用。
5.权利要求1，2中任意一项的化合物、及其药学上可接受的盐或水合物和权利要求3所述药物组合在制备抗肿瘤药物中的应用。
6.权利要求1，2中任意一项的化合物、及其药学上可接受的盐或水合物和权利要求3所述药物组合在制备治疗和/或预防乳腺癌，结肠癌，前列腺癌，胰腺癌，非小细胞肺癌，甲状腺乳头状癌，卵巢癌、黑色素瘤、或各种白血病中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311514297.9A CN117534658A (zh) | 2023-11-14 | 2023-11-14 | 一种靶向降解CK1α蛋白并激活P53蛋白的化合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311514297.9A CN117534658A (zh) | 2023-11-14 | 2023-11-14 | 一种靶向降解CK1α蛋白并激活P53蛋白的化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117534658A true CN117534658A (zh) | 2024-02-09 |
Family
ID=89785531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311514297.9A Pending CN117534658A (zh) | 2023-11-14 | 2023-11-14 | 一种靶向降解CK1α蛋白并激活P53蛋白的化合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117534658A (zh) |
-
2023
- 2023-11-14 CN CN202311514297.9A patent/CN117534658A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021129820A1 (zh) | 含螺环的喹唑啉化合物 | |
| JP2021098721A (ja) | 置換キナゾリン化合物およびその使用方法 | |
| CN109963844B (zh) | 一类抑制并降解酪氨酸蛋白激酶alk的化合物 | |
| US7855199B2 (en) | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient | |
| WO2022002018A1 (zh) | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 | |
| WO2022199547A1 (zh) | 一种7,9-二氢嘌呤衍生物及其制药用途 | |
| WO2015096640A1 (zh) | 含噻唑基雷帕霉素类衍生物及其应用 | |
| US20130005696A1 (en) | Bufadienolide derivatives, preparing process thereof, composition comprising the same and the use thereof | |
| CA2956788A1 (en) | Fumarate analogs and uses thereof in the treatment of an autoimmune disease or an inflammatory disease | |
| CN114195814A (zh) | 羟基萘酮-苯硼酸类化合物、制备方法和用途 | |
| AU2013289384B2 (en) | Combination therapy for the treatment of cancer and immunosuppression | |
| US8133888B2 (en) | Hydrazide containing taxane conjugates | |
| US6566341B1 (en) | Derivative of isoindigo, indigo and indirubin for the treatment of cancer | |
| CN117534658A (zh) | 一种靶向降解CK1α蛋白并激活P53蛋白的化合物及其应用 | |
| CN114773356B (zh) | 一种倍半萜衍生物、其药物组合物及其制备方法和用途 | |
| MXPA06008571A (es) | Derivados de pirrolo-pirimidina utiles para el tratamiento de enfermedades proliferativas. | |
| CN112341390B (zh) | 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途 | |
| CN114177177A (zh) | 一种乏氧肿瘤选择性激活前药的制备方法 | |
| WO2017112787A1 (en) | Glycoconjugates of anti-proliferative iron prochelators | |
| EP4155304A1 (en) | Compound used as ret kinase inhibitor and application thereof | |
| Wei et al. | Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer | |
| CN112279863A (zh) | Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用 | |
| KR101775440B1 (ko) | 벤조셀레노펜계 화합물 및 이를 포함하는 항체-약물 결합체 | |
| WO2019056375A1 (zh) | 酸敏感的吉非替尼轴向取代酞菁硅配合物及其制备方法和在医药上的应用 | |
| RU2801166C1 (ru) | [N'-(Изо)хинолилметилен]гидразиды 3-метокси-13,17-секоэстра-1,3,5(10)-триен-17-овой кислоты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |